US biotech company Moderna announced successful test, called phase 1, of experimental vaccine mRNA-1273 in people. The trial took place at the Kaiser Permanente Washington Health Research Institute in Seattle and was developed together with the US National Institute of Allergy and Infectious Disease (NIAID). It tested the vaccine on 45 males and nonpregnant females of 18 to 55 ages.
The vaccine itself is a small fragment of the coronavirus’s genetic code. Injected into the patient, it is not able to cause the disease or the symptoms of coronavirus, but it is enough to get a response from the immune system. People, participating clinical trials, were taking either low (25 microgram), middle (100 microgram) or high (250 microgram) dose. Each group consisted of 15 people, they were given two doses of the potential vaccine via intramuscular injection in the upper arm approximately 28 days apart.
Two weeks after the second dose was received, levels of binding antibodies in the 25 microgram group were at the levels generally seen in blood samples from people who recovered from the disease. Those who received 100 microgram had antibody level that “significantly exceeded” levels of recovered ones. Also the vaccine produced neutralizing antibodies against coronavirus – at least eight participants have shown the result, data for the other participants who were given the highest dose are not yet available.
Experiments on mice have shown that the vaccine could prevent the virus replicating in their lungs. Phase 3 of clinical trial is scheduled on July. If potential vaccine proves its safety and effectiveness, the manufacturing will possible start at the end of 2020 or at the beginning of the next year.